Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Plasma coenzyme Q10 status is impaired in selected genetic conditions

  • Montero, R.
  • Yubero, D.
  • Salgado, M.C.
  • González, M.J.
  • Campistol, J.
  • O''Callaghan, M.D.M.
  • Pineda, M.
  • Delgadillo, V.
  • Maynou, J.
  • Fernandez, G.
  • Montoya, J.
  • Ruiz-Pesini, E.
  • Meavilla, S.
  • Neergheen, V.
  • García-Cazorla, A.
  • Navas, P.
  • Hargreaves, I.
  • Artuch, R.
Identifying diseases displaying chronic low plasma Coenzyme Q10 (CoQ) values may be important to prevent possible cardiovascular dysfunction. The aim of this study was to retrospectively evaluate plasma CoQ concentrations in a large cohort of pediatric and young adult patients. We evaluated plasma CoQ values in 597 individuals (age range 1 month to 43 years, average 11 years), studied during the period 2005-2016. Patients were classified into 6 different groups: control group of healthy participants, phenylketonuric patients (PKU), patients with mucopolysaccharidoses (MPS), patients with other inborn errors of metabolism (IEM), patients with neurogenetic diseases, and individuals with neurological diseases with no genetic diagnosis. Plasma total CoQ was measured by reverse-phase high-performance liquid chromatography with electrochemical detection and ultraviolet detection at 275¿nm. ANOVA with Bonferroni correction showed that plasma CoQ values were significantly lower in the PKU and MPS groups than in controls and neurological patients. The IEM group showed intermediate values that were not significantly different from those of the controls. In PKU patients, the Chi-Square test showed a significant association between having low plasma CoQ values and being classic PKU patients. The percentage of neurogenetic and other neurological patients with low CoQ values was low (below 8%). In conclusión, plasma CoQ monitoring in selected groups of patients with different IEM (especially in PKU and MPS patients, but also in IEM under protein-restricted diets) seems advisable to prevent the possibility of a chronic blood CoQ suboptimal status in such groups of patients.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Muscle Involvement in a Large Cohort of Pediatric Patients with Genetic Diagnosis of Mitochondrial Disease

  • Jou, C.
  • Ortigoza-Escobar, J.D.
  • Ocallaghan, M.M.
  • Nascimento, A.
  • Darling, A.
  • Pias-Peleteiro, L.
  • Perez-Duenas, B.
  • Pineda, M.
  • Codina, A.
  • Arjona, C.
  • Armstrong, J.
  • Palau, F.
  • Ribes, A.
  • Gort, L.
  • Tort, F.
  • Navas, P.
  • Ruiz-Pesini, E.
  • Emperador, S.
  • Lopez-Gallardo, E.
  • Bayona-Bafaluy, P.
  • Montero, R.
  • Jimenez-Mallebrera, C.
  • Garcia-Cazorla, A.
  • Montoya, J.
  • Yubero, D.
  • Artuch, R.
Mitochondrial diseases (MD) are a group of genetic and acquired disorders which present significant diagnostic challenges. Here we report the disease characteristics of a large cohort of pediatric MD patients (n = 95) with a definitive genetic diagnosis, giving special emphasis on clinical muscle involvement, biochemical and histopathological features. Of the whole cohort, 51 patients harbored mutations in nuclear DNA (nDNA) genes and 44 patients had mutations in mitochondrial DNA (mtDNA) genes. The nDNA patients were more likely to have a reduction in muscle fiber succinate dehydrogenase (SDH) stains and in SDH-positive blood vessels, while a higher frequency of mtDNA patients had ragged red (RRF) and blue fibers. The presence of positive histopathological features was associated with ophthalmoplegia, myopathic facies, weakness and exercise intolerance. In 17 patients younger than two years of age, RRF and blue fibers were observed only in one case, six cases presented cytochrome c oxidase (COX) reduction/COX-fibers, SDH reduction was observed in five and all except one presented SDH-positive blood vessels. In conclusion, muscle involvement was a frequent finding in our series of MD patients, especially in those harboring mutations in mtDNA genes.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Molecular characterization of new FBXL4 mutations in patients with mtDNA depletion syndrome

  • Emperador, Sonia
  • Garrido-Pérez, Nuria
  • Amezcua-Gil, Javier
  • Gaudó, Paula
  • Andrés-Sanz, Julio Alberto
  • Yubero, Delia
  • Fernández-Marmiesse, Ana
  • O'Callaghan, Maria M
  • Ortigoza-Escobar, Juan D.
  • Iriondo, Marti
  • Ruiz-Pesini, Eduardo
  • García-Cazorla, Angels
  • Gil-Campos, Mercedes
  • Artuch, Rafael
  • Montoya, Julio
  • Bayona-Bafaluy, María Pilar
Encephalomyopathic mitochondrial DNA (mtDNA) depletion syndrome 13 (MTDPS13) is a rare genetic disorder caused by defects in F-box leucine-rich repeat protein 4 (FBXL4). Although FBXL4 is essential for the bioenergetic homeostasis of the cell, the precise role of the protein remains unknown. In this study, we report two cases of unrelated patients presenting in the neonatal period with hyperlactacidemia and generalized hypotonia. Severe mtDNA depletion was detected in muscle biopsy in both patients. Genetic analysis showed one patient as having in compound heterozygosis a splice site variant c.858+5G>C and a missense variant c.1510T>C (p.Cys504Arg) in FBXL4. The second patient harbored a frameshift novel variant c.851delC (p.Pro284LeufsTer7) in homozygosis. To validate the pathogenicity of these variants, molecular and biochemical analyses were performed using skin-derived fibroblasts. We observed that the mtDNA depletion was less severe in fibroblasts than in muscle. Interestingly, the cells harboring a nonsense variant in homozygosis showed normal mtDNA copy number. Both patient fibroblasts, however, demonstrated reduced mitochondrial transcript quantity leading to diminished steady state levels of respiratory complex subunits, decreased respiratory complex IV (CIV) activity, and finally, low mitochondrial ATP levels. Both patients also revealed citrate synthase deficiency. Genetic complementation assays established that the deficient phenotype was rescued by the canonical version of FBXL4, confirming the pathological nature of the variants. Further analysis of fibroblasts allowed to establish that increased mitochondrial mass, mitochondrial fragmentation, and augmented autophagy are associated with FBXL4 deficiency in cells, but are probably secondary to a primary metabolic defect affecting oxidative phosphorylation.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Leigh Syndrome in a Pedigree Harboring the m.1555A>G Mutation in the Mitochondrial 12S rRNA

  • Habbane, M.
  • Llobet, L.
  • Bayona-Bafaluy, M.P.
  • Bárcena, J.E.
  • Ceberio, L.
  • Gómez-Díaz, C.
  • Gort, L.
  • Artuch, R.
  • Montoya, J.
  • Ruiz-Pesini, E.
BACKGROUND: Leigh syndrome (LS) is a serious genetic disease that can be caused by mutations in dozens of different genes. METHODS: Clinical study of a deafness pedigree in which some members developed LS. Cellular, biochemical and molecular genetic analyses of patients'' tissues and cybrid cell lines were performed. RESULTS: mitochondrial DNA (mtDNA) m.1555A>G/MT-RNR1 and m.9541T>C/MT-CO3 mutations were found. The first one is a well-known pathologic mutation. However, the second one does not appear to contribute to the high hearing loss penetrance and LS phenotype observed in this family. CONCLUSION: The m.1555A>G pathological mutation, accompanied with an unknown nuclear DNA (nDNA) factor, could be the cause of the phenotypic manifestations in this pedigree.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Growth Differentiation Factor 15 is a potential biomarker of therapeutic response for TK2 deficient myopathy

  • Domínguez-González, Cristina|||0000-0001-5151-988X
  • Badosa, Carmen
  • Madruga-Garrido, Marcos
  • Martí, Itxaso|||0000-0003-0578-9568
  • Paradas, Carmen|||0000-0002-6917-2236
  • Ortez González, Carlos Ignacio|||0000-0001-8187-8103
  • Diaz-Manera, Jordi|||0000-0003-2941-7988
  • Berardo, Andres
  • Alonso Pérez, Jorge|||0000-0001-8866-5186
  • Trifunov, Selena|||0000-0002-1807-9621
  • Cuadras, Daniel|||0000-0001-8780-1764
  • Kalko, Susana G.|||0000-0002-6701-0233
  • Blázquez-Bermejo, Cora
  • Cámara, Yolanda|||0000-0003-2458-6942
  • Martí, Ramon A.|||0000-0002-8273-9540
  • Mavillard, Fabiola|||0000-0002-1460-0483
  • Martín, Miguel A.|||0000-0003-4741-772X
  • Montoya, Julio|||0000-0003-1770-6299
  • Ruiz-Pesini, Eduardo|||0000-0002-0269-7337
  • Villarroya, Joan
  • Montero, Raquel|||0000-0003-0609-5701
  • Villarroya, Francesc|||0000-0003-1266-9142
  • Artuch, R.|||0000-0002-3422-9685
  • Hirano, Michio|||0000-0002-7070-7402
  • Nascimento, Andrés
  • Jiménez Mallebrera, Cecilia|||0000-0001-8203-7103
GDF-15 is a biomarker for mitochondrial diseases. We investigated the application of GDF-15 as biomarker of disease severity and response to deoxynucleoside treatment in patients with thymidine kinase 2 (TK2) deficiency and compared it to FGF-21. GDF-15 and FGF-21 were measured in serum from 24 patients with TK2 deficiency treated 1-49 months with oral deoxynucleosides. Patients were grouped according to age at treatment and biomarkers were analyzed at baseline and various time points after treatment initiation. GDF-15 was elevated on average 30-fold in children and 6-fold in adults before the start of treatment. There was a significant correlation between basal GDF-15 and severity based on pretreatment distance walked (6MWT) and weight (BMI). During treatment, GDF-15 significantly declined, and the decrease was accompanied by relevant clinical improvements. The decline was greater in the paediatric group, which included the most severe patients and showed the greatest clinical benefit, than in the adult patients. The decline of FGF-21 was less prominent and consistent. GDF-15 is a potential biomarker of severity and of therapeutic response for patients with TK2 deficiency. In addition, we show evidence of clinical benefit of deoxynucleoside treatment, especially when treatment is initiated at an early age.